Lunai Bioworks Inc. (RENB)

Lunai Bioworks Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Selling, General & Admin	18.88	24.56	15.32	14.33	7.56	7.12
Research & Development	0.89	2.71	4.17	8.37	15.72	4.69
Operating Expenses	19.9	27.39	19.6	22.83	23.4	11.92
Operating Income	-19.9	-27.39	-19.6	-22.83	-23.4	-11.92
Interest Expense	-0.79	-1.01	-0.58	-0.37	-0.38	-0.1
Interest & Investment Income	0.1	-	-	-	0.01	0.05
Currency Exchange Gain (Loss)	-	-	-0	0	-0.03	0.15
Other Non Operating Income (Expenses)	-1.42	-1.42	-0.13	0.12	-	-
EBT Excluding Unusual Items	-22.01	-29.82	-20.3	-23.08	-23.8	-11.83
Impairment of Goodwill	-59.25	-11.64	-	-	-	-
Asset Writedown	-	-42.61	-18.96	-93.25	-	-
Other Unusual Items	21.82	3.42	-0.42	2.9	-3.05	0.41
Pretax Income	-59.23	-80.65	-39.68	-113.43	-26.85	-11.42
Income Tax Expense	-	-	-	0	-0.13	-
Net Income	-59.23	-80.65	-39.68	-113.43	-26.72	-11.42
Net Income to Common	-59.23	-80.65	-39.68	-113.43	-26.72	-11.42
Shares Outstanding (Basic)	157	96	56	53	47	46
Shares Outstanding (Diluted)	157	96	56	53	47	46
Shares Change (YoY)	111.54%	71.06%	7.12%	11.37%	1.81%	23.38%
EPS (Basic)	-0.38	-0.84	-0.71	-2.16	-0.57	-0.25
EPS (Diluted)	-0.38	-0.84	-0.71	-2.16	-0.57	-0.25
Free Cash Flow	-8.5	-11.04	-11.8	-15.74	-20.66	-10.64
Free Cash Flow Per Share	-0.05	-0.12	-0.21	-0.30	-0.44	-0.23
EBITDA	-19.77	-27.27	-19.48	-22.7	-23.28	-11.82
D&A For EBITDA	0.13	0.12	0.11	0.12	0.12	0.11
EBIT	-19.9	-27.39	-19.6	-22.83	-23.4	-11.92

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q